The outbreak of multinational pharmaceutical companies half-year results mixed these drugs or will become the first brand?

The new crown epidemic led to a significant reduction in patient demand and prescriptions, and then overlay the major pharmaceutical companies are facing patent expiration dilemma, the first half of 2020 can be described as "difficult", in the major pharmaceutical companies' financial results, all mentioned "the impact of the new crown outbreak led to performance damage."
in this situation, the new crown outbreak is not only the catalyst for the withdrawal of the heavy "old medicine", but also the new drug appearance of the screen, Johnson and Johnson's Dareto U-Sing, Roche's Ty Sanche, Sanofi's Duentpix, AstraZeneca's Infifan ... A series of new drugs that may be heavy-weight drugs in the future have become a "light" to save drug companies in the dismal run of the epidemic.
so, in the first half of 2020, looking at the performance of the major multinational pharmaceutical companies, which drug is in decline? Which medicine is on the rise? Who will be the future of multinational pharmaceutical companies in the top position? Johnson and Johnson Total Sales: US$39,027 million YoY: -3.8% In the first half of 2020, Johnson and Johnson's total sales for the reporting period were US$39,027 million, down 3.8% YoY.
and total sales reversed, Johnson and Johnson's pharmaceutical business Janssen achieved growth, with total sales in the first half of the year of $21.886 billion, up 5.4% YoY, notably, yangsen's growth rate was higher than in 2019, with total sales of $20.773 billion in the first half of 2019, up 2.8% YoY.
in Jansen's business growth, the previous heavyweight drugs and patents expired drugs are significantly disadvantaged, Yinglixi, lipido and boratezomi, etc. have shown a particularly significant decline, the first half of the decline of 12.9%, 10.5%, 57.7%.
, on the contrary, it is clearly the advantage of Jansen's new drug business, daretouu monoto-reminitator in the first half of the year achieved 31% year-on-year growth, Gusechi Yu monoto-retinitator achieved 41.8% year-on-year growth, Selexipag achieved 32.7% year-on-year growth, these three drugs The top three drugs in Yangsen's year-on-year growth, from Jansen's immune, tumor and pulmonary hypertension business, are generally approved for listing between 2015 and 2017, it can be seen that Johnson and Johnson's new drug business growth is obvious, the future may become the main growth point of Jansen's business.
from the perspective of research and development, in the first half of this year, Johnson and Johnson's research and development investment of $5.287 billion, down 4.3% year-on-year, the outbreak is now reasonable.
but from the second quarter of Johnson and Johnson's investment, Johnson and Johnson is overcoming the epidemic, research and development investment gradually rebounded, in the second quarter of 2.707 billion U.S. dollars, an increase of 1.5% year-on-year.
sales of new drugs provided strong support for Johnson and Johnson during the outbreak, and from the perspective of research and development pipeline, Johnson and Johnson has also been on the new drug continued to exert strength.
at present, Johnson and Johnson a total of 7 drugs in research, three of which are in adaptation to expand, it is worth noting that Johnson and Johnson announced in June that its new crown vaccine will enter the clinic by September, emergency use in January next year.
Roche Total Sales: CHF 29,281 million YoY: 1.3% In the first half of 2020, Roche achieved year-on-year growth of 29.281 billion Swiss francs, up 1.3% year-on-year, despite unprecedented challenges posed by the global epidemic of the new crown.

Roche's sales growth rate is similar to that of Johnson and Johnson, and under the new crown, Roche's pharmaceutical business, which has total sales of 23.202 billion Swiss francs in the first half of the year, up 3% year-on-year, accounting for more than 80% of Roche's total sales. Growth in
pharmaceutical business was concentrated in the oncology sector, with Sales of Anvitin 2.8 billion Swiss francs, Heseltine 2.2 billion Swiss francs, Merofa 1.9 billion Swiss francs and Tessan chi 1.3 billion Swiss francs.
, new products were also a major driver of growth in Roche's pharmaceutical business, with Tesanchi, Shu Youlio, Ocrevus and Hessele contributing more than CHF 5 billion in sales.
Shu Youlile sales of 1 billion Swiss francs, Ocrevus 2,076 million Swiss francs, Hessell8 837 million Swiss francs, of which, Sales of Tai Sanqi increased by 74% year-on-year, Shu Youlile increased by 94% year-on-year.
at the same time, Roche's semi-annual report also announced its sales in China, pharmaceutical sales reached 1.587 billion Swiss francs, up 7% year-on-year, diagnostic business 823 million U.S. dollars, up 16% year-on-year, from the sales figures can be seen that The Roche pharmaceutical business in the Chinese market affected by the outbreak, pharmaceutical business in 2019 year-on-year growth of 58%, Roche also reported that hospitals stopped receiving and delayed infusions led to the decline in the sale of the hospital.
not only the outbreak, biosimilar drug competition and health insurance is also a factor affecting its sales growth, Heseltine, Merofa and Anvitin three Roche products in recent years have been included in the health insurance led to a significant decline in sales revenue, and FuHong Hanxuan, Sansheng Guojian and other enterprises of biological-similar drugs also have an impact on Roche in the future can not be ignored.
Pfizer Total Sales: $23.829 billion YoY: -10% Pfizer's total revenue for the first half of 2020 was $23.829 billion, of which biopharmaceutical sales were $19.802 billion, or 83%, and Pfizer's business was down 35% from the same period in 2019 to $4.027 billion.
Pfizer's total revenue fell 10 percent in the first half of 2020 compared with the same period in 2019, excluding consumer health revenue in the first half of 2020, as Pfizer merged its healthcare business into GlaxoSmithKline in July 2019.

Pfizer's biopharmaceutical business grew 7 percent in the first half of 2020 due to strong sales of key brands such as ATTR-CM drug Vyndaqel /Vyndamax, anticoagulant eliquis, breast cancer drug Ibrance, oral JAK inhibitor Xtandi.
, the anticoagulant eliquis, with revenues of $2.572 billion, up 23% YoY, and Pfizer's Vyndaqel, which is used in the U.S. in May 2019 for the treatment of thyroxine-transporting protein amyloid cardiomyopathy (ATTR-CM), was launched in May 2019 and 9 in 2019 Vyndamax, the only drug to treat ATTR-CM, was launched in January, bringing explosive sales growth to $508 million, up 388 percent from a year earlier, while Japan and the European Union approved the ATTR-CM logo to grow nearly 140 percent in international markets.
in the mature drug sector due to multi-source generic competition that began in July 2019, the performance of the anti-epileptic and analgesic lyrica loss of exclusivity sales in the United States has declined significantly, with sales down 70 percent year-on-year and the U.S. market down 90 percent.
, Pfizer's business fell 35 percent in the first half of 2020 compared with the same period in 2019.
Pfizer's sales revenue in China grew 17 percent in the second quarter of 2020, partially offsetting a decline in its global business in the first half of the year.
in terms of the geographical distribution of the market, Pfizer's sales revenue in the U.S. and international markets in the first half of 2020 was broadly balanced.
the U.S. as Pfizer's largest market, with sales of $11,053 million, or 46 percent, and international sales of $12.776 billion, or 54 percent.
but the impact of the General Strong business, the U.S. market and international market performance have declined significantly.
on the decline in first-half results, Pfizer CEO Albert Bourla said, "About 25-30 products will be approved by 2022, 15 of which are expected to be heavy."
Pfizer's new architecture, which is expected to generate higher and more sustained revenue growth beyond 2020.
" Novartis Total Sales: $23.63 billion YoY: 3% Novartis CEO Vas Narasimhan commented on Novartis' first-half results, saying: "Despite the impact of the new crown, Novartis's performance in the first half of the year has been outstanding."
, although Novartis' sales and net profit fell 4% and 11% year-on-year in the second quarter, novarty's total sales in the first half were $23.63 billion, up 3% year-on-year, and net profit was $4.04 billion, up 2% year-on-year.

, Novartis's growth is also dependent on the contribution of new drugs, with novarty's total innovative drug sales of $18.943 billion in the first half of the year, accounting for more than 80 percent of Novartis's total sales.
its earnings showed that, in addition to the contribution of heavyweight "old drug" Entresto, the market share of three new drugs, Zolgensma, Cosentyx and Promacta Novartis, continued to grow, contributing $2.05 billion, $9.44 billion and $4.22 billion in sales, respectively, making it the main driver of Novartis's growth in the first half of the year.
Sanofi Total Sales: 17.18 billion euros YoY: 0.9% Sanofi CEO Paul Hudson commented in earnings report: "I am proud of the team's results delivered in the second quarter, and our earnings per share and Dupixent continued to grow despite the adverse effects of the new crown outbreak."
first half of the year, Sanofi achieved total sales of EUR 17.18 billion, up 0.9% year-on-year.
Sanofi's performance growth was also the focus of the pharmaceutical business, which reported total sales of EUR 13.02 billion, up 2.7% YoY, with Sanofi's total sales of Duentpix, a specialder dermatitis drug developed in partnership with Regenerative Yuan, reaching EUR 1.634 billion, up 93.8% YoY.
the drug was approved for sale in China in June, becoming the first biological agent in China to treat moderate to severe adhesion it in adults.
, dupixent will become the world's best-selling anti-inflammatory drug with sales of $9.386 billion in 2026, according to a drug sales forecast released by EvaluatePharma.
GlaxoSmithKline Total Sales: ?16.714 billion YoY: 8% GlaxoSmithKline's total revenue in the first half of 2020 was ?6.714 billion, up 8% YoY.
However, GSK's sales revenue declined in the second quarter of 2020 under the influence of the new crown outbreak.
GlaxoSmithKline's pharmaceutical and consumer health sectors were hit by the outbreak in the first quarter of 2020, particularly in vaccine stocks, with sales of ?7.624 billion in the second quarter of 2020, down 2% from the same period last year.

GlaxoSmithKline products cover the three major sectors of pharmaceuticals, vaccines, consumer health, 2020H1 product sales revenue of 16.687 billion pounds, accounting for about 99% of total revenue.
the largest share was in the pharmaceutical business, with sales of ?8,498 million, or about 51 per cent.
the biggest growth in respiratory pipeline products, driven by growth in the performance of chronic obstructive pulmonary disease (COPD) new drug Trelegy and asthma drug Nucala, with first-half sales of 1,754 million pounds in 2020, up 27% year-on-year.
followed by the consumer health business, with sales of 5.251 billion pounds, or about 31 percent.
report shows that GlaxoSmithKline's consumer health business grew 35 percent in the first half of 2020, driven by the merger with Pfizer.
vaccine business generated sales of ?2,938 million, or about 18 per cent.
the impact of the new crown outbreak has adversely affected sales of gSK's vaccines such as heredit, meningitis and shingles, while offsetting growth from shingrix, the shingles vaccine, in the first quarter of 2020, with sales of the vaccine business finally falling by 5% in the first half of 2020.
AstraZeneca's total sales: $12.629 billion Year-over-year: 12% impacted by the continued outbreak of the new crown, With a total revenue of $12.629 billion in the first half of 2020, AstraZeneca achieved revenue of 12% YoY, and grew in three major treatment areas and each sales region.
product sales rose 11 percent to $12.359 billion, representing 98 percent of total revenue, driven by performance in emerging markets and oncology.

in three major therapeutic areas, the oncology business grew 28 percent to $5,324 million, the cardiovascular and metabolic sectors grew 8 percent to $2,265 million, and the respiratory business grew 5 percent to $2,676 million.
, which was hit by a negative sales position in China under the new crown, reported a 11 percent decline in total revenue from its respiratory business in the second quarter of 2020 at $1.122 billion.
total revenue in the U.S. grew 13 percent to $4.177 billion in the first half of 2020 across all sales regions, 17 percent to $2,447 million in Europe and 9 percent in emerging markets to $4.329 billion, with China growing 10 percent to $2.659 billion.
, the new drug business grew 42 percent to $6,353 million, accounting for 50 percent of total global revenue (first half of 2019: 40 percent), with new drugs growing at 71 percent in emerging markets and generating revenue of $1.406 billion.
the third generation of EGFR-TKI cancer products Tagrisso and PD-L1 monoanti-Imfinzi in the 2020H1 cancer sector maintained strong growth in Both Europe and emerging countries, with Tagrisso 2020H1 with global sales of more than $2 billion;
on the other hand, Pulmicort sales in emerging markets fell 36 per cent to $371 million, compared with a 78 per cent drop of just $58 million in the second quarter, as Pumick's sales slumped in the Chinese market.